Canada markets close in 2 hours 6 minutes

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.4891+0.0091 (+0.61%)
As of 01:52PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.4800
Open1.4900
Bid1.4700 x 300
Ask1.4900 x 200
Day's Range1.4750 - 1.5300
52 Week Range1.0250 - 2.8500
Volume205,580
Avg. Volume912,795
Market Cap249.284M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.2100
Earnings DateAug 06, 2024 - Aug 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.68
  • GlobeNewswire

    atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

    NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company’s participation: Format: Virtual fireside chat and 1x1 investor meetingsDate and Time: Fireside c

  • GlobeNewswire

    atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

    ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024.The dose for Phase 2a was selected using pr

  • GlobeNewswire

    atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

    NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024. Details of the company’s participation: Format: Fireside ChatDate and Time: Thursday June 6 at 10:00 A.M. ETLocation: New YorkWebcast link